Advair revenue down again, but GSK looks to next-gen (and Zebulon) for replacement revenue

London-based GlaxoSmithKline (NYSE: GSK) reported quarterly earnings good enough for investors to trade the stock up more than 2 percent Wednesday. In the Triangle, however, those with a keen eye on the drug giant looked more closely at Advair, which again reported declining revenue. For the first half of 2015, GSK reported $1.37 billion in U.S. sales for Advair, an asthma drug, a figure down 19 percent from last year. The Triangle focuses on Advair because GSK leans heavily on its plant in Zebulon…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news